Pseudomonas aeruginosa continues to be a leading cause of nosocomial bacteremia and other serious, often life-threatening infections. The incidence of P. aeruginosa infection appears to be increasing. The resilience of Pseudomonas in the hospital environment, its endogenous virulence factors, and its current level of resistance to antimicrobials make it a formidable
BennettJV. Session I. Hospital-acquired infections and the altered host: nosocomial infections due to Pseudomonas. J Infect Dis1974; 130: 4–7.
3.
PollackM. Part III, 178. Pseudomonas aeruginosa. In: MandellGLDouglasRGJrBennettJE, eds. Principles and practice of infectious diseases. 2nd ed.New York: John Wiley, 1979: 1236–50.
ShooterRAWalkerKAWilliamsVRFaecal carriage of Pseudomonas aeruginosa in hospital patients: possible spread from patient to patient. Lancet1966; 2: 1331–4.
6.
AndersonETYoungLSHewittWL. Simultaneous antibiotic levels in “breakthrough” gram-negative rod bacteremia. Am J Med1976; 61: 493–7.
7.
GerdingDNLarsonTA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Am J Med1985; 79: 1–7.
8.
University Of Minnesota Hospitals. Clin Microbiol Lab Newsl1984; 9: 1.
9.
PhaneufDNeuHC. Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother1979; 16: 625–30.
10.
JonesRNThornsberryCBarryALFuchsPCGavanTLGerlachEH. Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole, and cefoxitin. J Antibiot1977; 30: 1107–14.
11.
NeuHC. The new beta-lactamase-stable cephalosporins. Ann Intern Med1982; 97: 408–19.
12.
LesarTSRotschaferJCStrandLMSolemLDZaskeDE. Gentamicin dosing errors with four commonly used nomograms. JAMA1982; 248: 1190–3.
JacksonGGRiffLJ. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis1971; 124: 185–91.
15.
NoonePParsonsTMCPattisonJRExperience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J1974; 1: 477–81.
16.
ZaskeDEBootmanJLSolemLDStrateRG. Increased burn patient survival with individualized doses of gentamicin. Surgery1982; 91: 142–9.
17.
CipolleRJSeifertRDZaskeDEStrateRG. Hospital acquired gram-negative pneumonias: response rate and dosage requirements with individualized tobramycin therapy. Ther Drug Monit1980; 2: 359–63.
18.
MooreRDSmithCRLietmanPS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis1984; 149: 443–8.
19.
PetersonCDKaatzBLAngaranDM. Ticarcillin and carbenicillin, a comparison. Drug Intell Clin Pharm1977; 11: 482–6.
20.
OliveSMogabgabWJHolmesBPollockBPaulingBBevilleR. Treatment of serious Pseudomonas infections with azlocillin. J Antimicrob Chemother1983; 11: 153–8.
21.
BaltchALSmithRP. Combinations of antibiotics against Pseudomonas aeruginosa. Am J Med1985; 79: 8–16.
